Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments in key therapeutic areas such as immunology, neuroscience, and oncology [2] - The company is advancing an innovative portfolio of therapeutics, utilizing proven drug development experience and proprietary drug development platforms [2] Therapeutic Areas and Programs - Biohaven's clinical and nonclinical programs include: - Kv7 ion channel modulation for epilepsy and mood disorders - Extracellular protein degradation for immunological diseases - TRPM3 antagonism for migraine and neuropathic pain - TYK2/JAK1 inhibition for neuroinflammatory disorders - Glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA) - Myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity - Antibody recruiting bispecific molecules and antibody drug conjugates for cancer [2] Upcoming Events - Vlad Coric, M.D., Chairman and CEO of Biohaven, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 8:15 am (PT) [1]